|218.90||+0.0900||+0.04%||Vol 336.59K||1Y Perf 124.98%|
|Apr 16th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||207.90||Analyst Rating||Strong Buy 1.12|
|Potential %||-5.03||Finscreener Ranking||★★★★ 54.30|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★ 57.52|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★ 54.84|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||6.86B||Earnings Rating||Strong Buy|
|Price Range Ratio 52W %||99.92||Earnings Date||10th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||10th May 2021|
|Estimated EPS Next Report||-0.02|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||323.85K|
|Avg. Monthly Volume||546.37K|
|Avg. Quarterly Volume||1.04M|
GW Pharmaceuticals Plc (NASDAQ: GWPH) stock closed at 218.9 per share at the end of the most recent trading day (a 0.04% change compared to the prior day closing price) with a volume of 336.60K shares and market capitalization of 6.86B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 1161 people. GW Pharmaceuticals Plc CEO is Justin David Gover.
The one-year performance of GW Pharmaceuticals Plc stock is 124.98%, while year-to-date (YTD) performance is 89.67%. GWPH stock has a five-year performance of 166.01%. Its 52-week range is between 87.07 and 219, which gives GWPH stock a 52-week price range ratio of 99.92%
GW Pharmaceuticals Plc currently has a PE ratio of -129.80, a price-to-book (PB) ratio of 9.28, a price-to-sale (PS) ratio of 16.90, a price to cashflow ratio of 19.00, a PEG ratio of 2.32, a ROA of -6.12%, a ROC of -7.39% and a ROE of -7.59%. The company’s profit margin is -12.53%, its EBITDA margin is -8.10%, and its revenue ttm is $406.57 Million , which makes it $12.89 revenue per share.
Of the last four earnings reports from GW Pharmaceuticals Plc, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.02 for the next earnings report. GW Pharmaceuticals Plc’s next earnings report date is 10th May 2021.
The consensus rating of Wall Street analysts for GW Pharmaceuticals Plc is Strong Buy (1.12), with a target price of $207.9, which is -5.03% compared to the current price. The earnings rating for GW Pharmaceuticals Plc stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
GW Pharmaceuticals Plc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
GW Pharmaceuticals Plc has a Buy technical analysis rating based on Technical Indicators (ADX : 40.12, ATR14 : 2.94, CCI20 : 123.91, Chaikin Money Flow : 0.29, MACD : 8.90, Money Flow Index : 50.30, ROC : 0.57, RSI : 78.08, STOCH (14,3) : 96.49, STOCH RSI : 1.00, UO : 75.95, Williams %R : -3.51), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of GW Pharmaceuticals Plc in the last 12-months were: Adam George (Option Excercise at a value of $1 526 182), Adam George (Sold 804 492 shares of value $8 962 251 ), Alicia Secor (Option Excercise at a value of $5), Cabot Brown (Option Excercise at a value of $5), Cabot Brown (Sold 4 020 shares of value $72 159 ), Catherine J. Mackey (Option Excercise at a value of $5), Christopher John Tovey (Option Excercise at a value of $159), Christopher John Tovey (Sold 122 028 shares of value $1 426 518 ), Darren S. Cline (Option Excercise at a value of $9), Douglas B. Snyder (Option Excercise at a value of $373), Douglas B. Snyder (Sold 83 508 shares of value $894 112 ), Geoffrey William Guy (Option Excercise at a value of $379), Geoffrey William Guy (Sold 1 747 152 shares of value $17 842 047 ), Justin David Gover (Option Excercise at a value of $851), Justin David Gover (Sold 180 000 shares of value $1 802 810 ), Scott Giacobello (Option Excercise at a value of $358), Volker Knappertz (Option Excercise at a value of $339), Volker Knappertz (Sold 60 000 shares of value $632 520 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.